Capital market

Most life science businesses have a considerable, recurrent need for funding, not least in connection with R&D projects in which the potential return is significant – and the risks equally high.

Biotech businesses and their investors are highly specialised and therefore look for advisers who are familiar with and appreciate the special conditions of their industry.

Our expertise

Kromann Reumert has extensive experience in advising on the establishment and capitalisation of life science businesses.

We have assisted in the set-up and funding of a long line of biotech businesses and are experts in advising biotech businesses and investors on:

• subsequent procurement of capital
• drafting of investor agreements
• agreements between existing and new shareholders and founders, etc.

We have substantial experience in life science IPOs and rendering advice to listed life science businesses as well as advising on subsequent capital increases on the OMX Nordic Exchange Copenhagen.